Study for Evaluation of Murlentamab (GM102) Anti-tumoral Activity in Colorectal Cancers
Phase 2
Completed
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2019-01-10
- Last Posted Date
- 2022-04-14
- Lead Sponsor
- GamaMabs Pharma
- Target Recruit Count
- 65
- Registration Number
- NCT03799731
- Locations
- 🇧🇪
UZ Gasthuisberg, Gent, Belgium
🇧🇪Cliniques Universitaires Saint-Luc, Brussels, Belgium
🇧🇪UZ Leuven, Leuven, Belgium
First In Human Safety, Pharmacokinetics and Anti-tumoral Activity of GM102 in Gynecological Cancers
- First Posted Date
- 2016-12-01
- Last Posted Date
- 2022-04-06
- Lead Sponsor
- GamaMabs Pharma
- Target Recruit Count
- 78
- Registration Number
- NCT02978755
- Locations
- 🇧🇪
UZ Leuven, Leuven, Belgium
🇧🇪Institut Bordet, Brussels, Belgium
🇫🇷CHU Besançon, Besançon, France
© Copyright 2025. All Rights Reserved by MedPath